Recursion Pharmaceuticals develops advanced technologies for drug discovery and development using machine learning and biology.
Kinnevik invests in Recursion's platform capability to fundamentally change drug discovery success rates over the long term, rather than focusing on near-term pipeline milestones like phase transitions that drive short-term investor attention.